Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease

被引:36
作者
Binukumar, B. K. [1 ]
Shukla, Varsha [1 ]
Amin, Niranjana D. [1 ]
Grant, Philip [1 ]
Bhaskar, M. [1 ]
Skuntz, Susan [1 ]
Steiner, Joseph [1 ]
Pant, Harish C. [1 ]
机构
[1] NINDS, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
CYCLIN-DEPENDENT KINASE-5; NIGROSTRIATAL DOPAMINERGIC-NEURONS; ALZHEIMERS-DISEASE; MOUSE MODEL; MICROGLIAL ACTIVATION; TREATED MICE; CDK5-MEDIATED PHOSPHORYLATION; MITOCHONDRIAL DYSFUNCTION; TAU HYPERPHOSPHORYLATION; OXIDATIVE STRESS;
D O I
10.1091/mbc.E15-06-0415
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. Recent evidence indicates that cyclin-dependent kinase 5 (Cdk5) is inappropriately activated in several neurodegenerative conditions, including PD. To date, strategies to specifically inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Previously we reported that TFP5 peptide has neuroprotective effects in animal models of Alzheimer's disease. Here we show that TFP5/TP5 selective inhibition of Cdk5/p25 hyperactivation in vivo and in vitro rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP/MPP+) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinflammation and apoptosis. Here we show selective inhibition of Cdk5/p25 hyperactivation by TFP5/TP5 peptide, which identifies the kinase as a potential therapeutic target to reduce neurodegeneration in Parkinson's disease.
引用
收藏
页码:4478 / 4491
页数:14
相关论文
共 67 条
[1]   Hyperphosphorylated tan and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5 [J].
Ahlijanian, MK ;
Barrezueta, NX ;
Williams, RD ;
Jakowski, A ;
Kowsz, KP ;
McCarthy, S ;
Coskran, T ;
Carlo, A ;
Seymour, PA ;
Burkhardt, JE ;
Nelson, RB ;
McNeish, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2910-2915
[2]   Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35 [J].
Amin, ND ;
Albers, W ;
Pant, HC .
JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 67 (03) :354-362
[3]   Rgs6 is Required for Adult Maintenance of Dopaminergic Neurons in the Ventral Substantia Nigra [J].
Bifsha, Panojot ;
Yang, Jianqi ;
Fisher, Rory A. ;
Drouin, Jacques .
PLOS GENETICS, 2014, 10 (12)
[4]   TFP5, a Peptide Derived from p35, a Cdk5 Neuronal Activator, Rescues Cortical Neurons from Glucose Toxicity [J].
Binukumar, B. K. ;
Zheng, Ya-Li ;
Shukla, Varsha ;
Amin, Niranjana D. ;
Grant, Philip ;
Pant, Harish C. .
JOURNAL OF ALZHEIMERS DISEASE, 2014, 39 (04) :899-909
[5]   Microglia-mediated neurotoxicity: uncovering the molecular mechanisms [J].
Block, Michelle L. ;
Zecca, Luigi ;
Hong, Jau-Shyong .
NATURE REVIEWS NEUROSCIENCE, 2007, 8 (01) :57-69
[6]  
BRION JP, 1995, AM J PATHOL, V147, P1465
[7]   MPP(+) SELECTIVELY AFFECTS CALCIUM HOMEOSTASIS IN MESENCEPHALIC CELL-CULTURES FROM EMBRYONAL C57/B16 MICE [J].
CHEN, TS ;
KOUTSILIERI, E ;
RAUSCH, WD .
JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1995, 100 (02) :153-163
[8]   Cdk5: mediator of neuronal death and survival [J].
Cheung, ZH ;
Ip, NY .
NEUROSCIENCE LETTERS, 2004, 361 (1-3) :47-51
[9]   Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation [J].
Chung, Young C. ;
Bok, Eugene ;
Huh, Sue H. ;
Park, Ju-Young ;
Yoon, Sung-Hwa ;
Kim, Sang R. ;
Kim, Yoon-Seong ;
Maeng, Sungho ;
Park, Sung Hyun ;
Jin, Byung K. .
JOURNAL OF IMMUNOLOGY, 2011, 187 (12) :6508-6517
[10]   Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinson's Disease [J].
Chung, Young C. ;
Kim, Sang R. ;
Jin, Byung K. .
JOURNAL OF IMMUNOLOGY, 2010, 185 (02) :1230-1237